Navigation Links
Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis
Date:7/29/2009

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new six month safety and efficacy results from its fourth Phase II clinical trial using its proprietary, orally-active non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis. Consistent with previously reported six month (Petal Study) and three month (Lilac Petal Study) results, a favorable safety profile and clinically meaningful efficacy have again been confirmed through month six of the Lilac Petal Study. This newly available data also provides clinical confirmation of Neurocrine's extensive pharmacologic modeling related to the elagolix dose-response continuum. The outcome of primary interest at month six was the impact of the elagolix 250 mg dose on bone mineral density (BMD) as measured by dual energy X-ray absorptiometry (DXA) scanning.

Over the six month treatment period, elagolix 150 mg once daily had minimal impact on BMD (-0.80% mean change from baseline, femur; -0.66% mean change from baseline, spine). The 250 mg once daily dose, as expected, had slightly greater percentage change from baseline at month six (-1.0% femur, -1.6% spine). The 150 mg once daily BMD profile in this Lilac Petal Study is consistent with that previously demonstrated in the six-month Petal Study.

"We selected the 150 mg and 250 mg once daily doses for this study based upon predictions generated from extensive modeling of dose, estradiol and bone mineral density relationships. Prior to this study we anticipated that the 250 mg dose would provide exposure such that we would start to see an increased impact on bone mineral density in a small portion of study subjects. The Lilac Petal data confirm that our modeling of the dose-response curve was accurate," said C
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Successfully Completes 100-Litre cGMP Production of REOLYSIN(R)
2. Blue Marble Energy Corp. Announces Successful Close of Series A Financing
3. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
4. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
5. Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UKs Veterinary Laboratories Agency
6. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
7. Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
8. Orthocrat Announces Successful Implementation of TraumaCad at UPMC Mercy
9. Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
10. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
11. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company ... for the treatment of prostate, brain, lung, head and ... for the second quarter and six months of fiscal ... --> --> Revenue was $1.19 ... ended December 31, 2015, a 12% increase compared to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark Research, a ... promotion of two long-standing principal investigators (PI) to the roles of Chief Medical ... Development. , Dr. Laurence Chu, a Benchmark Research PI in the Austin office, ...
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC reports the ... Sonalinkā„¢ remote monitoring. The inaugural launch of this new technology occurred over the ... Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. , ...
(Date:2/10/2016)... ... 10, 2016 , ... Global Stem Cells Group, ... Global Stem Cells Network (GSCN) and its affiliate Global Medical Training Network ... adipose and bone marrow therapies. , Through the new collaboration, Global Stem ...
Breaking Biology Technology:
(Date:1/28/2016)... SYNA ), a leading developer of human interface solutions, today ... --> --> Net revenue ... to the comparable quarter last year to $470.5 million. Net income ... $0.93 per diluted share. --> ... 2016 grew 9 percent over the prior year period to $60.3 ...
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
Breaking Biology News(10 mins):